UNC School of Medicine researchers led by Brian Conlon, PhD, discover how molecules called rhamnolipids could make common aminoglycoside antibiotics effective against the toughest Staph infections.
Staphylococcus aureus bacteria are a major cause of serious infections that often persist despite antibiotic treatment, but scientists at the UNC School of Medicine have now discovered a way to make these bacteria much more susceptible to some common antibiotics.
The scientists, in a study published in Cell Chemical Biology, found that adding molecules called rhamnolipids can make aminoglycoside antibiotics, such as tobramycin, hundreds of times more potent against S. aureus – including the strains that are otherwise very hard to kill. The rhamnolipids effectively loosen up the outer membranes of S. aureus cells so that aminoglycoside molecules can get into them more easily.
“There’s a great need for new ways to kill bacteria that tolerate or resist standard antibiotics, and to that end we found that altering membrane permeability to induce aminoglycoside uptake is an extremely effective strategy against S. aureus,” said study senior author Brian Conlon, PhD, an assistant professor in the department of microbiology and immunology at the UNC School of Medicine.
The U.S. Centers for Disease Control has estimated that in 2017 there were more than 119,000 cases of serious bloodstream Staph infections in the United States, of which more than 20,000 were fatal.
Standard treatments for many strains of the S. aureus do not kill the bacteria, either because the bacteria have genetically acquired specific antibiotic resistance or because they grow in the body in a way that makes them inherently less vulnerable. For example, S. aureus can adapt its metabolism to survive in low-oxygen zones in abscesses or in the mucus-filled lungs of people with cystic fibrosis. In these environments, the bacterial outer wall or membrane becomes relatively impermeable to aminoglycosides, such as tobramycin.
Conlon and colleagues, including first author Lauren Radlinski, a PhD candidate in the Conlon laboratory, found in a 2017 study that rhamnolipids greatly enhance tobramycin’s potency against standard test strains of S. aureus. Rhamnolipids are small molecules produced by another bacterial species, Pseudomonas aeruginosa, and are thought to be one of P. aeruginosa’s natural weapons against other bacteria in the wild. At high doses they make holes in rival bacteria’s cell membranes. The UNC researchers found that rhamnolipids greatly boost the uptake of tobramycin molecules, even at low doses where they have no independent anti-bacterial effect.
In the new study, Conlon, Radlinski and colleagues tested rhamnolipid-tobramycin combinations against S. aureus populations that are particularly hard to kill in ordinary clinical practice. The researchers found that rhamnolipids boost tobramycin’s potency against:
• S. aureus growing in low-oxygen niches;
• MRSA (methicillin-resistant S. aureus), which are a family of dangerous S. aureus variants with genetically acquired treatment resistance;
• tobramycin-resistant S. aureus strains isolated from cystic fibrosis patients;
• and “persister” forms of S. aureus that normally have reduced susceptibility to antibiotics because they grow so slowly.
Radlinski said, “Tobramycin doses that normally would have little or no effect on these S. aureus populations quickly killed them when combined with rhamnolipids.”
Conlon, Radlinski, and colleagues determined that rhamnolipids even at low doses alter the S. aureusmembrane in a way that makes it much more permeable to aminoglycosides. Each antibiotic in this family that they tested – including tobramycin, gentamicin, amikacin, neomycin, and kanamycin – had its potency enhanced. The experiments showed, moreover, that this potency-boosting strategy is effective not just against S. aureus but several other bacterial species, including Clostridioides difficile (C-diff), which is a major cause of serious, often-fatal diarrheal illness among the elderly and patients in hospitals.
Rhamnolipids come in many variants, and the scientists now hope to determine if there is an optimal variant that works powerfully against other bacteria while having little or no toxic effect on human cells. The team also plans to study other microbe-vs.-microbe weapons to find new ways to enhance the potency of existing antibiotics.
“There’s a huge number of bacterial interspecies interactions that could be influencing how well our antibiotics work,” Radlinski said. “We aim to find them with the ultimate goal of improving the efficacy of current therapeutics and slowing the rise of antibiotic resistance.”
The Latest on: Antibiotic resistance
via Google News
The Latest on: Antibiotic resistance
- Fighting antibiotic resistant superbugs with viruseson January 19, 2021 at 2:41 pm
There's been advances in the fight to combat antibiotic resistant superbugs. One of the Australian scientists at the forefront of this research Jeremy Barr of Monash University talks to Jesse about ...
- Unlocking 'the shape of water' in mechanisms of antibiotic resistanceon January 19, 2021 at 12:55 pm
Researchers captured and comparted hi-res images of ribosome structures from sensitive and resistant bacteria and report that a water molecule needed for antibiotic binding was not present in the ...
- Research establishes antibiotic potential for cannabis moleculeon January 19, 2021 at 11:03 am
The main nonpsychoactive component of cannabis has been shown to kill the bacteria responsible for gonorrhoea, meningitis and legionnaires disease, which could lead to the first new class of ...
- £100m awarded to Oxford for research into antibiotic resistanceon January 19, 2021 at 9:33 am
The University of Oxford has been awarded a grant of £100 million pounds to study our growing resistance to antibiotics. The current pandemic has focused minds on the importance of medicine, and the ...
- Oxford University's new mega centre to combat global antibiotic resistanceon January 19, 2021 at 9:13 am
Antimicrobial resistance (AMR) currently causes an estimated 1.5 million excess deaths each year and could cause over 10 million deaths per year by 2050.
- Oxford given £100m for antibiotic resistance researchon January 19, 2021 at 5:45 am
Britain's Oxford University has received a donation of £100 million (112 million euros, US$136 million) to research growing resistance to antibiotics, the university announced on Tuesday. The sum, ...
- Oxford given £100mn for antibiotic resistance researchon January 19, 2021 at 4:53 am
Increasing antibiotic resistance already causes 1.5 million excess deaths each year, the University of Oxford has said.
- New research into antibiotic resistance has been funded - but what does it mean?on January 19, 2021 at 2:03 am
The University of Oxford has been given £100 million to launch a new institute that aims to combat the growing issue of resistance to antibiotics.
- Oxford research tackles threat of antibiotic resistanceon January 18, 2021 at 6:07 pm
There will be 50 researchers working in the new Ineos Oxford Institute for Antimicrobial Resistance, addressing the "over-use and mis-use" of antibiotics, which the university warned could cause 10 ...
- Researchers show Irish soil can offer more hope in fight against antibiotic resistanceon January 17, 2021 at 2:24 am
Antibiotic resistant superbugs could kill up to 1.3 million people in Europe by 2050—the World Health Organization (WHO) describes the problem as "one of the biggest threats to global health ...
via Bing News